1. Home
  2. REF vs OBX Comparison

REF vs OBX Comparison

Compare REF & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reformation Inc. Common Stock

REF

Reformation Inc. Common Stock

SELL

Current Price

$18.41

Market Cap

904.5M

ML Signal

SELL

Logo Obsidian Therapeutics Inc. Common Stock

OBX

Obsidian Therapeutics Inc. Common Stock

HOLD

Current Price

$10.99

Market Cap

861.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REF
OBX
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
904.5M
861.1M
IPO Year
2026
2026

Fundamental Metrics

Financial Performance
Metric
REF
OBX
Price
$18.41
$10.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$19.25
★ $39.00
AVG Volume (30 Days)
★ 388.9K
344.9K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.39
N/A
Revenue Next Year
$16.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.85
$11.52
52 Week High
$17.26
$39.00

Technical Indicators

Market Signals
Indicator
REF
OBX
Relative Strength Index (RSI) 68.53 42.05
Support Level $12.55 $11.84
Resistance Level N/A $19.97
Average True Range (ATR) 0.99 1.24
MACD 0.22 0.29
Stochastic Oscillator 96.91 39.31

Price Performance

Historical Comparison
REF
OBX

About REF Reformation Inc. Common Stock

Reformation Inc sells apparel and accessories through its website, company-owned retail stores, wholesale channels, and other distribution channels in the United States and internationally. Its product portfolio includes dresses, bottoms, tops, sweaters, and accessories. The company focuses on womenswear and sources materials and products through its supply chain operations. The majority of the company's revenue was derived from the sale of its apparel and accessories, including clothing, shoes, and bags, through e-commerce and retail. Geographically, the maximum revenue is generated from the United States.

About OBX Obsidian Therapeutics Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Share on Social Networks: